Towards pathogen inactivation of red blood cells and whole blood targeting viral DNA/RNA: design, technologies, and future prospects for developing countries.
Identifieur interne : 000007 ( Main/Exploration ); précédent : 000006; suivant : 000008Towards pathogen inactivation of red blood cells and whole blood targeting viral DNA/RNA: design, technologies, and future prospects for developing countries.
Auteurs : Victor J. Drew [Taïwan] ; Lassina Barro [Taïwan] ; Jerard Seghatchian [Royaume-Uni] ; Thierry Burnouf [Taïwan]Source :
- Blood transfusion = Trasfusione del sangue [ 1723-2007 ] ; 2017.
Abstract
Over 110 million units of blood are collected yearly. The need for blood products is greater in developing countries, but so is the risk of contracting a transfusion-transmitted infection. Without efficient donor screening/viral testing and validated pathogen inactivation technology, the risk of transfusion-transmitted infections correlates with the infection rate of the donor population. The World Health Organization has published guidelines on good manufacturing practices in an effort to ensure a strong global standard of transfusion and blood product safety. Sub-Saharan Africa is a high-risk region for malaria, human immunodeficiency virus (HIV), hepatitis B virus and syphilis. Southeast Asia experiences high rates of hepatitis C virus. Areas with a tropical climate have an increased risk of Zika virus, Dengue virus, West Nile virus and Chikungunya, and impoverished countries face economical limitations which hinder efforts to acquire the most modern pathogen inactivation technology. These systems include Mirasol(®) Pathogen Reduction Technology, INTERCEPT(®), and THERAFLEX(®). Their procedures use a chemical and ultraviolet or visible light for pathogen inactivation and significantly decrease the threat of pathogen transmission in plasma and platelets. They are licensed for use in Europe and are used in several other countries. The current interest in the blood industry is the development of pathogen inactivation technologies that can treat whole blood (WB) and red blood cell (RBC). The Mirasol system has recently undergone phase III clinical trials for treating WB in Ghana and has demonstrated some efficacy toward malaria inactivation and low risk of adverse effects. A 2(nd)-generation of the INTERCEPT(®) S-303 system for WB is currently undergoing a phase III clinical trial. Both methodologies are applicable for WB and components derived from virally reduced WB or RBC.
DOI: 10.2450/2017.0344-16
PubMed: 28488960
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000818
- to stream PubMed, to step Curation: 000818
- to stream PubMed, to step Checkpoint: 000818
- to stream Ncbi, to step Merge: 000B24
- to stream Ncbi, to step Curation: 000B24
- to stream Ncbi, to step Checkpoint: 000B24
- to stream Main, to step Merge: 000007
- to stream Main, to step Curation: 000007
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Towards pathogen inactivation of red blood cells and whole blood targeting viral DNA/RNA: design, technologies, and future prospects for developing countries.</title><author><name sortKey="Drew, Victor J" sort="Drew, Victor J" uniqKey="Drew V" first="Victor J" last="Drew">Victor J. Drew</name><affiliation wicri:level="1"><nlm:affiliation>International PhD Program of Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>International PhD Program of Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University</wicri:regionArea><wicri:noRegion>Taipei Medical University</wicri:noRegion></affiliation></author><author><name sortKey="Barro, Lassina" sort="Barro, Lassina" uniqKey="Barro L" first="Lassina" last="Barro">Lassina Barro</name><affiliation wicri:level="1"><nlm:affiliation>International PhD Program of Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>International PhD Program of Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University</wicri:regionArea><wicri:noRegion>Taipei Medical University</wicri:noRegion></affiliation></author><author><name sortKey="Seghatchian, Jerard" sort="Seghatchian, Jerard" uniqKey="Seghatchian J" first="Jerard" last="Seghatchian">Jerard Seghatchian</name><affiliation wicri:level="3"><nlm:affiliation>International Consultancy in Blood Components Quality Improvement/Safety, Audit/Inspection and DDR Strategy, London, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>International Consultancy in Blood Components Quality Improvement/Safety, Audit/Inspection and DDR Strategy, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Burnouf, Thierry" sort="Burnouf, Thierry" uniqKey="Burnouf T" first="Thierry" last="Burnouf">Thierry Burnouf</name><affiliation wicri:level="1"><nlm:affiliation>International PhD Program of Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>International PhD Program of Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University</wicri:regionArea><wicri:noRegion>Taipei Medical University</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28488960</idno><idno type="pmid">28488960</idno><idno type="doi">10.2450/2017.0344-16</idno><idno type="wicri:Area/PubMed/Corpus">000818</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000818</idno><idno type="wicri:Area/PubMed/Curation">000818</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000818</idno><idno type="wicri:Area/PubMed/Checkpoint">000818</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000818</idno><idno type="wicri:Area/Ncbi/Merge">000B24</idno><idno type="wicri:Area/Ncbi/Curation">000B24</idno><idno type="wicri:Area/Ncbi/Checkpoint">000B24</idno><idno type="wicri:doubleKey">1723-2007:2017:Drew V:towards:pathogen:inactivation</idno><idno type="wicri:Area/Main/Merge">000007</idno><idno type="wicri:Area/Main/Curation">000007</idno><idno type="wicri:Area/Main/Exploration">000007</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Towards pathogen inactivation of red blood cells and whole blood targeting viral DNA/RNA: design, technologies, and future prospects for developing countries.</title><author><name sortKey="Drew, Victor J" sort="Drew, Victor J" uniqKey="Drew V" first="Victor J" last="Drew">Victor J. Drew</name><affiliation wicri:level="1"><nlm:affiliation>International PhD Program of Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>International PhD Program of Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University</wicri:regionArea><wicri:noRegion>Taipei Medical University</wicri:noRegion></affiliation></author><author><name sortKey="Barro, Lassina" sort="Barro, Lassina" uniqKey="Barro L" first="Lassina" last="Barro">Lassina Barro</name><affiliation wicri:level="1"><nlm:affiliation>International PhD Program of Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>International PhD Program of Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University</wicri:regionArea><wicri:noRegion>Taipei Medical University</wicri:noRegion></affiliation></author><author><name sortKey="Seghatchian, Jerard" sort="Seghatchian, Jerard" uniqKey="Seghatchian J" first="Jerard" last="Seghatchian">Jerard Seghatchian</name><affiliation wicri:level="3"><nlm:affiliation>International Consultancy in Blood Components Quality Improvement/Safety, Audit/Inspection and DDR Strategy, London, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>International Consultancy in Blood Components Quality Improvement/Safety, Audit/Inspection and DDR Strategy, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Burnouf, Thierry" sort="Burnouf, Thierry" uniqKey="Burnouf T" first="Thierry" last="Burnouf">Thierry Burnouf</name><affiliation wicri:level="1"><nlm:affiliation>International PhD Program of Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>International PhD Program of Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University</wicri:regionArea><wicri:noRegion>Taipei Medical University</wicri:noRegion></affiliation></author></analytic><series><title level="j">Blood transfusion = Trasfusione del sangue</title><idno type="ISSN">1723-2007</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Over 110 million units of blood are collected yearly. The need for blood products is greater in developing countries, but so is the risk of contracting a transfusion-transmitted infection. Without efficient donor screening/viral testing and validated pathogen inactivation technology, the risk of transfusion-transmitted infections correlates with the infection rate of the donor population. The World Health Organization has published guidelines on good manufacturing practices in an effort to ensure a strong global standard of transfusion and blood product safety. Sub-Saharan Africa is a high-risk region for malaria, human immunodeficiency virus (HIV), hepatitis B virus and syphilis. Southeast Asia experiences high rates of hepatitis C virus. Areas with a tropical climate have an increased risk of Zika virus, Dengue virus, West Nile virus and Chikungunya, and impoverished countries face economical limitations which hinder efforts to acquire the most modern pathogen inactivation technology. These systems include Mirasol(®) Pathogen Reduction Technology, INTERCEPT(®), and THERAFLEX(®). Their procedures use a chemical and ultraviolet or visible light for pathogen inactivation and significantly decrease the threat of pathogen transmission in plasma and platelets. They are licensed for use in Europe and are used in several other countries. The current interest in the blood industry is the development of pathogen inactivation technologies that can treat whole blood (WB) and red blood cell (RBC). The Mirasol system has recently undergone phase III clinical trials for treating WB in Ghana and has demonstrated some efficacy toward malaria inactivation and low risk of adverse effects. A 2(nd)-generation of the INTERCEPT(®) S-303 system for WB is currently undergoing a phase III clinical trial. Both methodologies are applicable for WB and components derived from virally reduced WB or RBC.</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li><li>Taïwan</li></country><region><li>Angleterre</li><li>Grand Londres</li></region><settlement><li>Londres</li></settlement></list><tree><country name="Taïwan"><noRegion><name sortKey="Drew, Victor J" sort="Drew, Victor J" uniqKey="Drew V" first="Victor J" last="Drew">Victor J. Drew</name></noRegion><name sortKey="Barro, Lassina" sort="Barro, Lassina" uniqKey="Barro L" first="Lassina" last="Barro">Lassina Barro</name><name sortKey="Burnouf, Thierry" sort="Burnouf, Thierry" uniqKey="Burnouf T" first="Thierry" last="Burnouf">Thierry Burnouf</name></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Seghatchian, Jerard" sort="Seghatchian, Jerard" uniqKey="Seghatchian J" first="Jerard" last="Seghatchian">Jerard Seghatchian</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000007 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000007 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaGhanaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:28488960
|texte= Towards pathogen inactivation of red blood cells and whole blood targeting viral DNA/RNA: design, technologies, and future prospects for developing countries.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:28488960" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SidaGhanaV1
| This area was generated with Dilib version V0.6.31. |  |